mp.weixin.qq.com·· 4 hours agoPickScore91
CTTQ Reports Phase II First-Line Data for TQB2102 Plus Benmelstobart and Capecitabine in HER2-Positive Advanced Gastric Cancer at ESMO, Triplet ORR 84.2%
In brief
Chia Tai Tianqing (CTTQ) presented Phase II results at ESMO 2026 for TQB2102 combined with benmelstobart and capecitabine as first-line therapy for HER2-positive advanced gastric cancer, with the triplet regimen achieving an ORR of 84.2%. As of September 3, 2026, the TQB2102-II-04 study (NCT06767800) had enrolled 86 patients; the 6 mg/kg triplet arm showed an ORR of 95.8% (23/24), a cORR of 91.7% and a DCR of 100%, and this dose was selected as the recommended dose for the subsequent Phase III study.
Why it matters
The Phase II study compared doses by ORR, DCR and safety and selected 6 mg/kg as the recommended Phase III dose.
Source: mp.weixin.qq.com · mp.weixin.qq.com